Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is ...

India’s weight loss category is undergoing a dynamic transformation triggered by scientific improvements, pharma innovation, ...

WeightWatchers has plans to file for bankruptcy in the coming months, a source familiar with the matter said on Wednesday.

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

Novo Nordisk’s Vikrant Shrotriya on accelerating Wegovy’s launch, pricing strategy, and building long-term obesity care ...

Pfizer said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury ...

As demand soared for weight-loss drugs, price signals worked.

WeightWatchers is planning to file for bankruptcy after failing to compete against the rise of ‘quick-fix’ weight loss tools, ...

Thanks to a confluence of cultural forces—including the rise of plant-based diets and trendy fiber supps (like psyllium husk, ...